Cingulate

Cingulate Current Assets

The Current Assets of Cingulate (CING) as of Nov 11, 2026 is 12.00 M USD. In the previous year, Current Assets was 12.61 M USD — a change of -4.80% (lower).

Current Assets

12.00 MUSD

YoY

-4.80%

Last updated:

Current Assets of Cingulate is 2025 12.00 M USD. Current Assets of Cingulate was 2024 12.61 M USD. It decreases by -4.80% lower compared to the previous year.

The Cingulate Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
975,077.00 USD
Jan 1, 2020
1.79 M USD
Jan 1, 2021
18.88 M USD
Jan 1, 2022
7.87 M USD
Jan 1, 2023
563,950.00 USD
Jan 1, 2024
12.61 M USD
Jan 1, 2025
12.00 M USD
The Cingulate Current Assets history
YEARCurrent AssetsYoY
12.00 MUSD-4.80%
12.61 MUSD+2,135.29%
563,950.00USD-92.83%
7.87 MUSD-58.35%
18.88 MUSD+956.03%
1.79 MUSD+83.38%
975,077.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Current Assets of Cingulate is 12.00 M USD in 2025.

Current Assets of Cingulate changed from 12.61 M USD to 12.00 M USD, representing a -4.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Cingulate since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cingulate

All Key Metrics — Cingulate